Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development

Area of Science:

• Virology
• Drug Discovery
• Structural Biology

Background:

• Severe acute respiratory syndrome-associated coronavirus (SARS-CoV-2) emerged in 2019, causing a global pandemic.
• Existing vaccines and treatments like Remdesivir show limitations due to moderate vaccination rates and viral evolution.
• Targeting viral proteases, specifically papain-like protease (PLpro) and main protease (Mpro), is critical for inhibiting SARS-CoV-2 replication and host immune response suppression.

Purpose of the Study:

• To review the latest developments in small-molecule and peptide inhibitors for SARS-CoV-2 PLpro and Mpro.
• To highlight the role of structural biology in facilitating the discovery and optimization of these antiviral agents.

Main Methods:

• Literature review of recent studies on SARS-CoV-2 protease inhibitors.
• Analysis of biochemical assays and cell-based viral replication studies.
• Examination of the contribution of structural biology to inhibitor design.

Main Results:

• Several potential small-molecule and peptide inhibitors targeting SARS-CoV-2 PLpro and Mpro have been identified.
• These candidates demonstrate inhibitory effects in biochemical assays and reduce viral replication in cellular models.
• Structural biology approaches have significantly aided in understanding protease function and guiding inhibitor development.

Conclusions:

• Further optimization of identified inhibitors is necessary to enhance prophylactic and therapeutic efficacy against SARS-CoV-2.
• Targeting viral proteases remains a promising strategy for developing novel antiviral therapies.
• Continued research integrating structural biology is essential for advancing SARS-CoV-2 drug discovery.